EGFR×FGFR2b bsADC / Earendil Labs - LARVOL DELTA

Engineering and development of a novel bispecific ADC targeting EGFR and FGFR2b (AACR 2026) - "Bemarituzumab, an afucosylated FGFR2b monoclonal antibody has shown efficacy in the clinical study for the treatment in patients with FGFR2b‑positive GC and GEJ cancer...Our EGFR×FGFR2b bsAb function as a partial FGFR2b ligand blocker, and only weakly inhibiting FGF7 while sparing FGF10‑mediated signaling, thus with the potential to reduce on‑target toxicity associated with FGF7/FGF10 blockade. Several bsAb ADC were generated with various cytotoxic payloads and are being tested in vitro and in vivo studies."

ADC • Bispecific • Gastric Cancer • Oncology • Solid Tumor • EGFR • FGF10 • FGF7 • FGFR2